- Home
- TWN vs HUMA Comparison
TWN vs HUMA Comparison
Compare TWN & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWN
- HUMA
- Stock Information
- Founded
- TWN 1986
- HUMA 2004
- Country
- TWN Hong Kong
- HUMA United States
- Employees
- TWN N/A
- HUMA N/A
- Industry
- TWN Trusts Except Educational Religious and Charitable
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- TWN Finance
- HUMA Health Care
- Exchange
- TWN Nasdaq
- HUMA Nasdaq
- Market Cap
- TWN 346.7M
- HUMA 324.0M
- IPO Year
- TWN N/A
- HUMA N/A
- Fundamental
- Price
- TWN $58.10
- HUMA $1.69
- Analyst Decision
- TWN
- HUMA Strong Buy
- Analyst Count
- TWN 0
- HUMA 7
- Target Price
- TWN N/A
- HUMA $10.00
- AVG Volume (30 Days)
- TWN 20.1K
- HUMA 7.6M
- Earning Date
- TWN 01-01-0001
- HUMA 11-07-2025
- Dividend Yield
- TWN 1.10%
- HUMA N/A
- EPS Growth
- TWN N/A
- HUMA N/A
- EPS
- TWN N/A
- HUMA N/A
- Revenue
- TWN N/A
- HUMA $818,000.00
- Revenue This Year
- TWN N/A
- HUMA N/A
- Revenue Next Year
- TWN N/A
- HUMA $1,686.52
- P/E Ratio
- TWN N/A
- HUMA N/A
- Revenue Growth
- TWN N/A
- HUMA N/A
- 52 Week Low
- TWN $25.22
- HUMA $1.15
- 52 Week High
- TWN $41.51
- HUMA $6.77
- Technical
- Relative Strength Index (RSI)
- TWN 71.02
- HUMA 48.22
- Support Level
- TWN $56.10
- HUMA $1.65
- Resistance Level
- TWN $57.00
- HUMA $1.90
- Average True Range (ATR)
- TWN 1.80
- HUMA 0.11
- MACD
- TWN 0.09
- HUMA -0.01
- Stochastic Oscillator
- TWN 90.06
- HUMA 40.58
About TWN Taiwan Fund Inc. (The)
Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.